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CA4P induced vascular damage, increased tumor hypoxia, 
and increased TEM numbers in MMTV-PyMT mammary 
tumors. (A) H&E staining shows a marked increase in 
tumor necrosis (N) 24 hours after 50 mg/kg CA4P. (B) 
Staining with anti-PIMO shows increased hypoxia (red). 
(C) Tumor sections stained with anti-CD31 antibodies 
show reduced lumen of blood vessels (white) 24 hours 
after 50 mg/kg CA4P. (D) Tumors stained with DAPI (to 
show cell nuclei; blue), anti-F4/80 (green), and anti-TIE2 
(red). Yellow arrows denote F4/80+TIE2+ TEMs; F4/80–
TIE2+ structures represent blood vessels. (E) Number 
of all F4/80+ cells/field and F4/80+TIE2+ TEMs/field (by 
immunofluorescent staining; see D above) and proportion 
(%) of F4/80+TIE2– and F4/80+TIE2+ cells (TEMs) in viable 
cells obtained from dispersed tumors (by flow cytometric 
analysis; see Supplemental Figure 1). Scale bars: 50 μm. 
*P < 0.05, **P < 0.01, ***P < 0.001, compared with relevant 
control group. NS, no statistical difference (P > 0.05).
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Inhibition of tumor recruitment of CXCR4+ TEMs increases the therapeutic efficacy of CA4P. (A) CXCL12 expression, determined by 
immunofluorescence staining (see Supplemental Figure 3), was increased in MMTV-PyMT tumors 24 hours after injection with 50 mg/kg CA4P. 
(B and C) Flow cytometric analysis of dispersed MMTV-PyMT tumors shows that (B) the majority of F4/80+TIE2+ TEMs express CXCR4 and 
the MFI for CXCR4 is higher for TEMs than TIE2– TAMs and (C) CXCR4 expression/TEM is upregulated after CA4P treatment. (D) The CXCR4 
inhibitor, AMD-3100, inhibits recruitment of TEMs, but not TIE2– TAMs, to MMTV-PyMT tumors and increases CA4P-induced tumor necrosis. 
n > 5 mice per group. *P < 0.05; **P < 0.01. (E) Twice daily i.p. injections of 5 mg/kg AMD-3100 (for the period indicated) enhanced the effects 
of 3 daily i.p. injections of 50 mg/kg CA4P on the growth of N202 tumors. Statistical analysis in E employed the nonlinear mixed effects model 
described in the Supplemental Methods.
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Conditional depletion of TEMs increases the efficacy of CA4P treatment. (A) N202 tumors excised 24 hours after the last of 3 daily i.p. injections 
of CA4P or saline in the presence or absence of GCV to deplete TEMs were stained with DAPI (blue), anti-F4/80 (green), anti-TIE2 (red), and 
anti-MMP9 (white). TEMs are highlighted with yellow arrows; non-TAMs that express MMP9 are shown with white arrows. Scale bar: 50 μm. 
(B and C) Changes in TEM numbers and tumor necrotic area 24 hours and 72 hours after last CA4P injection. n = 6 mice per group. *P < 0.05.
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